Skip to content

Study · Randomized controlled trial · n = 20 · 2011

6 results

Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study.

Jonasson AF, Edwall L, Uvnäs-Moberg K

Menopause international25 Nov 2011Cited by 30 (Europe PMC)

PMID22120944 (opens in a new tab)DOI10.1258/mi.2011.011030 (opens in a new tab)PepBankPUB-22120944
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with vaginal atrophy, topical oxytocin gel normalised the vaginal epithelium in seven of 10 women, and in none of 10 given placebo (significant difference).

    In plain wordsIn postmenopausal women with vaginal atrophy, oxytocin gel made the vaginal lining healthier in seven of 10 women, and in none given placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseNormalisation of vaginal epithelium
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Vaginal and urogenital health · Reproductive and sexual health
    Studied dose
    Dose not stated · intravaginal · seven daysAs given in this study (human).

    Source sentences

    Summary
    After treatment with the oxytocin gel, the examination showed that the vaginal epithelium of seven of the 10 participants in the oxytocin group had become healthier and normalized.
    4 context sentences
    Summary · context
    No change in these parameters was observed among the 10 participants in the placebo group.
    Summary · context
    This difference between the oxytocin and placebo groups was significant (P= 0.003).
    Summary · context
    Twenty postmenopausal women (at least two years after menopause) with symptoms of vaginal atrophy such as vaginal dryness, pain, itching, discomfort and bleeding during intercourse were enrolled in the study when visual inspection of the vagina had confirmed that their mucosa was atrophic.
    Summary · context
    The participants were randomized to intravaginal treatment with either oxytocin or placebo gel for seven days.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with vaginal atrophy, the effect of oxytocin gel on the morphological appearance of the vaginal mucosa was almost significant versus placebo.

    In plain wordsIn postmenopausal women, oxytocin gel did not clearly change the look of the vaginal lining compared with placebo (almost significant).

    Peptide
    Oxytocin
    Outcome
    No significant changeNormalisation of vaginal mucosa morphology (almost significant)
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Vaginal and urogenital health · Reproductive and sexual health
    Studied dose
    Dose not stated · intravaginal · seven daysAs given in this study (human).

    Source sentences

    Summary
    The effect of oxytocin to normalize the morphological appearance of the vaginal mucosa was almost significant when compared with the placebo group (P= 0.07).
    2 context sentences
    Summary · context
    Twenty postmenopausal women (at least two years after menopause) with symptoms of vaginal atrophy such as vaginal dryness, pain, itching, discomfort and bleeding during intercourse were enrolled in the study when visual inspection of the vagina had confirmed that their mucosa was atrophic.
    Summary · context
    The participants were randomized to intravaginal treatment with either oxytocin or placebo gel for seven days.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with vaginal atrophy, seven participants on oxytocin gel and four on placebo reported symptom relief after seven days; no test is reported.

    In plain wordsIn postmenopausal women, seven on oxytocin gel and four on placebo reported symptom relief after seven days; no statistical test is given.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedRelief of vaginal atrophy symptoms
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Vaginal and urogenital health · Reproductive and sexual health
    Studied dose
    Dose not stated · intravaginal · seven daysAs given in this study (human).

    Source sentences

    Summary
    Seven participants in the active group and four in the placebo group reported relief of symptoms of vaginal atrophy after seven days of applying the gel.
    2 context sentences
    Summary · context
    Twenty postmenopausal women (at least two years after menopause) with symptoms of vaginal atrophy such as vaginal dryness, pain, itching, discomfort and bleeding during intercourse were enrolled in the study when visual inspection of the vagina had confirmed that their mucosa was atrophic.
    Summary · context
    The participants were randomized to intravaginal treatment with either oxytocin or placebo gel for seven days.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with vaginal atrophy, circulating estradiol did not differ between the oxytocin and placebo groups before and after treatment.

    In plain wordsIn postmenopausal women, oxytocin gel did not change blood estradiol levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCirculating estradiol
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · intravaginal · seven daysAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference between the circulating levels of estradiol and oxytocin in both the oxytocin and placebo groups before and after treatment.
    2 context sentences
    Summary · context
    Twenty postmenopausal women (at least two years after menopause) with symptoms of vaginal atrophy such as vaginal dryness, pain, itching, discomfort and bleeding during intercourse were enrolled in the study when visual inspection of the vagina had confirmed that their mucosa was atrophic.
    Summary · context
    The participants were randomized to intravaginal treatment with either oxytocin or placebo gel for seven days.
  5. 05HumanRandomized controlled trialPharmacokinetics

    In postmenopausal women with vaginal atrophy, circulating oxytocin did not differ between the oxytocin gel and placebo groups before and after treatment.

    In plain wordsIn postmenopausal women, oxytocin gel did not raise blood oxytocin levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeCirculating oxytocin
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravaginal · seven daysAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference between the circulating levels of estradiol and oxytocin in both the oxytocin and placebo groups before and after treatment.
    2 context sentences
    Summary · context
    Twenty postmenopausal women (at least two years after menopause) with symptoms of vaginal atrophy such as vaginal dryness, pain, itching, discomfort and bleeding during intercourse were enrolled in the study when visual inspection of the vagina had confirmed that their mucosa was atrophic.
    Summary · context
    The participants were randomized to intravaginal treatment with either oxytocin or placebo gel for seven days.
  6. 06HumanRandomized controlled trialSafety outcome

    In postmenopausal women with vaginal atrophy, none of the participants reported any side-effects of the study gels.

    In plain wordsIn postmenopausal women using oxytocin or placebo gel for seven days, nobody reported side-effects.

    Peptide
    Oxytocin
    Outcome
    No significant changeSide-effects
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · intravaginal · seven daysAs given in this study (human).

    Source sentences

    Summary
    None of the participants reported any side-effects.
    2 context sentences
    Summary · context
    Twenty postmenopausal women (at least two years after menopause) with symptoms of vaginal atrophy such as vaginal dryness, pain, itching, discomfort and bleeding during intercourse were enrolled in the study when visual inspection of the vagina had confirmed that their mucosa was atrophic.
    Summary · context
    The participants were randomized to intravaginal treatment with either oxytocin or placebo gel for seven days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 2/3NCT05627791

Effects of Vaginal Oxytocin Gel on Vaginal Cytologic Parameters in Postmenopausal Woman

Department of Medical Services Ministry of Public Health of Thailandn = 630 Nov 2022 to 28 Aug 2023

Vaginal Atrophy · Oxytocin Gel · Postmenopausal Women · Vaginal Maturation Index

Trial pageClinicalTrials.govUpdated 31 Aug 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.